Pavmed (NSDQ:PAVM) said today it closed a previously announced public offering, raising approximately $3.9 million which it plans to use for working capital and general corporate purposes. Money raised in the round came through the sale of 2.4 million shares of its common stock at a price of $1.80 per share, the New York City-based company […]
Pavmed
Pavmed prices $4.3m offering
Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net […]
Pavmed registers $90m offering
Pavmed (NSDQ:PAVM) has registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The New York City-based company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth […]
Pavmed sets terms for warrants offering
Pavmed (NSDQ:PAVM) said today that it set the terms for a forthcoming rights offering, saying it plans to issue a single unit for each share of common stock. Each unit will include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 each, the New York City-based company said. Last […]
Pavmed cuts warrant price again
Pavmed (NSDQ:PAVM) said today it would cut the cash exercise price of each of its Series W warrants from $2.50 to $2.00 apiece. This is the second price cut that Pavmed has given for its outstanding warrants. Each of the New York-based company’s outstanding warrants were exercisable at $5.00 apiece for one share of common stock […]
Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device
Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of […]
Pavmed files FDA 510(k) for CarpX carpal tunnel device
Pavmed (NSDQ:PAVM) said today it filed a 510(k) application with the FDA for its CarpX minimally invasive device designed to treat carpal tunnel syndrome. The CarpX is a percutaneous device designed to allow the operating physician to relieve compression of the median nerve without a surgical incision. The system combines a balloon catheter with bipolar radio-frequency […]
Pavmed shares climb after Q3 EPS beat
Shares in Pavmed Inc. (NSDQ:PAVM) rose today after the medical device maker beat expectations on Wall Street with its third quarter results. The N.Y.-based company posted a net loss of -$5.37 million, or -40¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -178.5% compared with the same period last year. Get the […]
Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system
Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday. The move is based on a recommendation from the FDA, the company said. Get the full story at our sister site, Drug […]
Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for the 3 months ended June 30, for bottom-line growth of 25% compared with the same period last year. Get the full story at our sister […]
Pavmed raises $5m in private placement
Pavmed (NSDQ:PAVM) said today it closed a $5 million private placement through the sale of senior notes and Series S warrants. Funding in the private placement came from Scopia Holdings, who elected Dr. David Battleman to New York-based Pavmed’s board of directors as part of the financing. “I look forward to joining the PAVmed team as a […]
